Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. [electronic resource]
- Cancer research Jul 1999
- 3442-50 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
0008-5472
Adenosine Triphosphate--metabolism Amino Acid Sequence Amino Acid Substitution Amsacrine--pharmacology Animals Antineoplastic Agents--chemistry Binding Sites CHO Cells Carcinoma, Small Cell--drug therapy Catalysis--drug effects Consensus Sequence Cricetinae Cricetulus DNA Damage DNA Mutational Analysis DNA Topoisomerases, Type II--genetics DNA, Neoplasm--genetics DNA, Single-Stranded--genetics Drug Resistance, Neoplasm--genetics Enzyme Inhibitors--pharmacology Etoposide--pharmacology Humans Lung Neoplasms--drug therapy Molecular Sequence Data Mutagenesis, Site-Directed Point Mutation Protein Isoforms--antagonists & inhibitors Razoxane--chemistry Recombinant Fusion Proteins--metabolism Saccharomyces cerevisiae--genetics Structure-Activity Relationship Thiobarbiturates--pharmacology Topoisomerase II Inhibitors Tumor Stem Cell Assay